Arca
Skip to content
Tools
Tools

Prostate cancer

Drug research and approvals for prostate cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 1,229 studies of prostate cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 219 drug trials for it since 2013, FDA has 1 approved and 2 open orphan designations naming it, and the EU has 17 authorised medicines for it.

  • Recruiting worldwide: 1,229
  • Trials authorized in Canada: 219
  • FDA orphan approvals: 1
  • EU medicines: 17

Recruiting now

Newest posted first, of 1,229 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition or a subtype of it, from ChEMBL's drug indications

Approved 24 of 27

Phase 3 12 of 90

  • PrednisoneCastration-resistant prostate cancer · Glucocorticoid receptor agonist
  • BicalutamideCastration-resistant prostate cancer · Androgen Receptor antagonist
  • AbirateroneCastration-resistant prostate cancer · Cytochrome P450 17A1 inhibitor
  • GoserelinCastration-resistant prostate cancer · Gonadotropin-releasing hormone receptor agonist
  • PaclitaxelCastration-resistant prostate cancer · Tubulin inhibitor
  • CarboplatinCastration-resistant prostate cancer · DNA inhibitor
  • NivolumabCastration-resistant prostate cancer · Programmed cell death protein 1 inhibitor
  • IpilimumabCastration-resistant prostate cancer · Cytotoxic T-lymphocyte protein 4 inhibitor
  • PembrolizumabCastration-resistant prostate cancer · Programmed cell death protein 1 inhibitor
  • GozetotideCastration-resistant prostate cancer · Diagnostic agent
  • DexamethasoneCastration-resistant prostate cancer · Glucocorticoid receptor agonist
  • KetoconazoleCastration-resistant prostate cancer · Cytochrome P450 51 inhibitor

Phase 2 12 of 296

  • CyclophosphamideCastration-resistant prostate cancer · DNA inhibitor
  • SargramostimCastration-resistant prostate cancer · Granulocyte-macrophage colony-stimulating factor receptor agonist
  • CelecoxibCastration-resistant prostate cancer · Cyclooxygenase-2 inhibitor
  • Testosterone cypionateCastration-resistant prostate cancer · Androgen Receptor agonist
  • CabozantinibCastration-resistant prostate cancer · Vascular endothelial growth factor receptor 2 inhibitor
  • GefitinibCastration-resistant prostate cancer · Epidermal growth factor receptor erbB1 inhibitor
  • SorafenibCastration-resistant prostate cancer · Serine/threonine-protein kinase RAF inhibitor
  • DurvalumabCastration-resistant prostate cancer · Programmed cell death 1 ligand 1 inhibitor
  • IxabepiloneCastration-resistant prostate cancer · Tubulin inhibitor
  • VinorelbineCastration-resistant prostate cancer · Tubulin inhibitor
  • TestosteroneCastration-resistant prostate cancer · Androgen Receptor agonist
  • ImatinibCastration-resistant prostate cancer · Tyrosine-protein kinase ABL inhibitor

Phase 1 or earlier 12 of 170

  • FludarabineCastration-resistant prostate cancer
  • MidazolamCastration-resistant prostate cancer · GABA-A receptor; anion channel positive allosteric modulator
  • RimiducidCastration-resistant prostate cancer
  • HiltonolCastration-resistant prostate cancer
  • NezastomigCastration-resistant prostate cancer
  • SonidegibCastration-resistant prostate cancer · Smoothened homolog inhibitor
  • TemozolomideDNA inhibitor
  • VismodegibCastration-resistant prostate cancer · Smoothened homolog inhibitor
  • AZD3514Castration-resistant prostate cancer · Androgen Receptor modulator
  • CC-115Castration-resistant prostate cancer · Serine/threonine-protein kinase mTOR inhibitor
  • DactolisibCastration-resistant prostate cancer · Serine/threonine-protein kinase mTOR inhibitor
  • PicoplatinCastration-resistant prostate cancer · DNA cross-linking agent

How its trials ended

5,809 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 1,321 whose ending is known, 28% met their primary endpoint, 9% missed it and 63% stopped early.

  • Completed, result not reported2,23739%
  • Ongoing1,65128%
  • Status unknown60010%
  • Stopped: other or unclear4147%
  • Met its primary endpoint3666%
  • Stopped: enrollment or feasibility2234%
  • Missed its primary endpoint1222%
  • Stopped: sponsor or business decision781%
  • Stopped: lack of efficacy681%
  • Stopped: funding331%
  • Stopped: safety17<1%

Trials authorized in Canada

The 10 newest of 219; search them all in Canada trials
Nov 6, 2026A phase 1 open-label, multicenter study to evaluate the safety, tolerability and pharmacokinetics of MK-1568 as monotherapy in participants with metastatic…MK-1568Merck & Co. (MSD)Pending
Oct 23, 2026Master protocol: MK-2870-U01 master protocol: a phase 1/2 platform study to evaluate the safety and efficacy of sacituzumab tirumotecan (sac-tmt; MK-2870) as…MK-2870 (sacituzumab tirumotecan) / Opevesostat (MK-5684) / Abiraterone acetate…Merck & Co. (MSD)Pending
Oct 9, 2026Actfirst: a phase III, open-label, multi-center, randomized study comparing AAA817+arpi versus standard of care in adult participants with psma-positive…[225AC]AC-PSMA-617 (AAA817) / Zytiga / XtandiNovartis PharmaceuticalsPending
Sep 25, 2026A phase 3, open-label study of risvutatug rezetecan versus docetaxel in participants with metastatic, chemo-naïve androgen pathway modulator-resistant prostate…Risvutatug rezetecan (GSK5764227)GSKPending
Sep 24, 2026A phase 2, open-label platform study utilizing a master protocol to study risvutatug rezetecan as monotherapy or in combination with other treatments in adult…Risvutatug rezetecan (GSK5764227)GSKPending
Aug 4, 2026A phase 3, randomized, open-label study of rinzimetostat (ORIC-944) in combination with darolutamide compared with arpi or docetaxel in patients with…Rinzimetostat (ORIC-944) / DarolutamideOric PharmaceuticalsPending
Jul 28, 2026Psmaction: a phase II/III, open-label, international, multicenter, randomized study of AAA817 versus standard of care in the treatment of adult participants…[225AC]AC-PSMA-617 (AAA817)Novartis PharmaceuticalsPending
Jul 23, 2026A phase 3 randomized study to evaluate the safety and efficacy of risvutatug rezetecan, a B7-H3 antibody drug conjugate (ADC) in participants with metastatic…Risvutatug rezetecan (GSK5764227)GSKOngoing
Jul 15, 2026A randomized, double-blind, placebo-controlled, 2-cohort, phase III study of saruparib combined with physician’s choice of androgen receptor pathway inhibitor…Saruparib (AZD5305) / DarolutamideAstraZeneca PharmaceuticalsOngoing
Jun 19, 2026A phase I, open-label, multicenter study of JANX007 in subjects with metastatic castration resistant prostate cancerJANX007Janux TherapeuticsPending

FDA orphan designations

Approved first, then open designations, newest first
Nov 13, 1996NovantroneIn combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory…SeronoApproved
Jun 6, 2026PembrolizumabTreatment of neuroendocrine prostate cancer (NEPC)Merck, Sharp & Dohme LLC.Designated
May 6, 1997SuraminTreatment of hormone-refractory prostate cancer.Warner-Lambert CompanyDesignated

Medicines authorised in the EU

Newest first; 15 of 17
Sep 29, 2023Degarelix AccordDegarelix · genericAccord Healthcare S.L.U.EMA ↗
Apr 19, 2023AkeegaNiraparib; abiraterone acetateEMA ↗
May 24, 2022CamceviLeuprorelinAccord Healthcare S.L.U.EMA ↗
Apr 29, 2022OrgovyxRelugolixAccord Healthcare S.L.U.EMA ↗
Aug 20, 2021Abiraterone MylanAbiraterone acetate · genericMylan Pharmaceuticals LimitedEMA ↗
Jun 24, 2021Abiraterone KrkaAbiraterone acetate · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Apr 26, 2021Abiraterone AccordAbiraterone · genericAccord Healthcare S.L.U.EMA ↗
Aug 28, 2020Cabazitaxel AccordCabazitaxel · genericAccord Healthcare S.L.U.EMA ↗
Mar 27, 2020NubeqaDarolutamideBayer AGEMA ↗
Jan 14, 2019ErleadaApalutamideJanssen-Cilag International NVEMA ↗
May 21, 2017AxuminFluciclovine (18F)Blue Earth Diagnostics Ireland LtdEMA ↗
Nov 13, 2013XofigoRadium Ra223 dichlorideBayer AGEMA ↗
Jun 21, 2013XtandiEnzalutamideAstellas Pharma Europe B.V.EMA ↗
Sep 5, 2011ZytigaAbirateroneJanssen-Cilag InternationalEMA ↗
Mar 17, 2011JevtanaCabazitaxelSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.